Literature DB >> 30543814

NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/β-catenin signalling pathway in clear cell renal cell carcinoma.

Qin Wang1, Handong Ding2, Yinghua He1, Xiaofeng Li1, Yahui Cheng1, Qingqing Xu1, Yue Yang1, Guiyi Liao2, Xiaoming Meng1, Cheng Huang3, Jun Li4.   

Abstract

NLRC5, a newly discovered member of the NLR family, has been reported to regulate immune responses and promote cell proliferation, migration, and invasion in hepatocellular carcinoma. However, to date, the potential regulatory roles and molecular mechanisms by which NLRC5 affects the development and progression of clear cell renal cell carcinoma (ccRCC) remain largely unknown. In this study, human clinical data from The Cancer Genome Atlas database revealed that increased NLRC5 expression was associated with advanced stage and poor prognosis in ccRCC patients. Moreover, experimental results showed that NLRC5 is aberrantly overexpressed in human ccRCC tissues and cell lines. Depletion of NLRC5 attenuated ccRCC cell proliferation, migration, and invasion and suppressed ccRCC growth in a nude mouse model. By contrast, overexpression of NLRC5 promoted the proliferation, migration, and invasion of ccRCC cells in vitro. Additionally, NLRC5 expression is not only positively correlated with β-catenin but also coordinates the activation of the downstream Wnt/β-catenin signalling pathway. Together, our data suggest that NLRC5 may be a potential therapeutic target for ccRCC therapy.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  NLRC5; Wnt/β-catenin pathway; ccRCC

Mesh:

Substances:

Year:  2018        PMID: 30543814     DOI: 10.1016/j.canlet.2018.11.024

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

Review 1.  MHC class I transactivator NLRC5 in host immunity, cancer and beyond.

Authors:  Steven X Cho; Saptha Vijayan; Ji-Seung Yoo; Toshiyuki Watanabe; Ryota Ouda; Ning An; Koichi S Kobayashi
Journal:  Immunology       Date:  2020-08-03       Impact factor: 7.397

2.  NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer.

Authors:  Yijun Fan; Zhen Dong; Yuchuan Shi; Shiying Sun; Bing Wei; Lei Zhan
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

3.  Transcriptomic Profiling of Fibropapillomatosis in Green Sea Turtles (Chelonia mydas) From South Texas.

Authors:  Nicholas B Blackburn; Ana Cristina Leandro; Nina Nahvi; Mariana A Devlin; Marcelo Leandro; Ignacio Martinez Escobedo; Juan M Peralta; Jeff George; Brian A Stacy; Thomas W deMaar; John Blangero; Megan Keniry; Joanne E Curran
Journal:  Front Immunol       Date:  2021-02-24       Impact factor: 7.561

Review 4.  The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.

Authors:  Akhil Shukla; Maryse Cloutier; Madanraj Appiya Santharam; Sheela Ramanathan; Subburaj Ilangumaran
Journal:  Int J Mol Sci       Date:  2021-02-17       Impact factor: 5.923

5.  Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease.

Authors:  Jessica A Pilsworth; Dawn R Cochrane; Samantha J Neilson; Bahar H Moussavi; Daniel Lai; Aslı D Munzur; Janine Senz; Yi Kan Wang; Sina Zareian; Ali Bashashati; Adele Wong; Jacqueline Keul; Annette Staebler; Hannah S van Meurs; Hugo M Horlings; Stefan Kommoss; Friedrich Kommoss; Esther Oliva; Anniina Em Färkkilä; Blake Gilks; David G Huntsman
Journal:  J Pathol Clin Res       Date:  2021-01-11

6.  Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma.

Authors:  Lei Lv; Qinqin Wei; Zhiwen Wang; Yujia Zhao; Ni Chen; Qiyi Yi
Journal:  Front Bioeng Biotechnol       Date:  2021-07-09

Review 7.  NLRC5: A Potential Target for Central Nervous System Disorders.

Authors:  Lu Zhang; Cui Jiao; Lingjuan Liu; Aiping Wang; Li Tang; Yi Ren; Peng Huang; Jie Xu; Dingan Mao; Liqun Liu
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

8.  VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.

Authors:  Jinbo Sun; Qisheng Tang; Yongheng Gao; Wei Zhang; Zhining Zhao; Fan Yang; Xiangnan Hu; Dan Zhang; Yong Wang; Huizhong Zhang; Bin Song; Bo Zhang; He Wang
Journal:  J Exp Clin Cancer Res       Date:  2020-06-08

9.  BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma.

Authors:  Pei Wan; Zhilin Chen; Weifeng Zhong; Huiming Jiang; Zhicheng Huang; Dong Peng; Qiang He; Nanhui Chen
Journal:  Oncol Rep       Date:  2020-10-08       Impact factor: 3.906

10.  NLRC5, a valuable marker for the diagnosis and prognostic assessment of hepatocellular carcinoma.

Authors:  Xiu-Wen Zhang; Run-Da Wu; Huan Wang; Fei Hu; Zhong-Qi Mao
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.